Pan-cancer immunogenomic analyses reveal sex disparity in the efficacy of cancer immunotherapy

Immune checkpoint inhibitors (ICIs), such as blockers of programmed cell death 1 (PD-1), programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen-4  are promising cancer therapeutics which have already been used in a variety of cancers and exhibit huge benefits [1]. However, sex-based dimorphism on the efficacy of ICIs was recently revealed in various cancers. It was suggested that male cancer patients benefit more from ICIs than the female co unterparts [2], while the underlying mechanism still remains to be elucidated.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research